Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sunshine Biopharma (SBFM)
NASDAQ:SBFM
Holding SBFM?
Track your performance easily
SBFM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.11 - $570.00
Previous CloseN/A
Volume70.59K
Average Volume (3M)305.41K
Market Cap
$7.66M
Enterprise Value-$7.61M
Total Cash (Recent Filing)$57.45K
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Apr 08, 2025EPS Estimate
0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-155.59
Shares Outstanding2,708,341
10 Day Avg. Volume167,559
30 Day Avg. Volume305,407
Standard Deviation4.07
R-Squared0.01
Alpha0.81
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.17
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.99
Enterprise Value/Revenue-0.23
Enterprise Value/Gross Profit-0.91
Enterprise Value/Ebitda1.93
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Sunshine Biopharma News
PremiumCompany Announcements
Sunshine Biopharma Appoints New Chief Commercial Officer
Ownership Overview
1.11% Insiders
<0.01%
Mutual Funds
<0.01% Other Institutional Investors
98.89% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
SBFM FAQ
What was Sunshine Biopharma’s price range in the past 12 months?
Sunshine Biopharma lowest stock price was $2.10 and its highest was $570.00 in the past 12 months.
What is Sunshine Biopharma’s market cap?
Sunshine Biopharma’s market cap is $7.66M.
When is Sunshine Biopharma’s upcoming earnings report date?
Sunshine Biopharma’s upcoming earnings report date is Apr 08, 2025 which is in 77 days.
How were Sunshine Biopharma’s earnings last quarter?
Sunshine Biopharma released its earnings results on Nov 06, 2024. The company reported -$0.94 earnings per share for the quarter, beating the consensus estimate of -$535 by $534.06.
Is Sunshine Biopharma overvalued?
According to Wall Street analysts Sunshine Biopharma’s price is currently Overvalued.
Does Sunshine Biopharma pay dividends?
Sunshine Biopharma does not currently pay dividends.
What is Sunshine Biopharma’s EPS estimate?
Sunshine Biopharma’s EPS estimate is 0.01.
How many shares outstanding does Sunshine Biopharma have?
Sunshine Biopharma has 2,708,341 shares outstanding.
What happened to Sunshine Biopharma’s price movement after its last earnings report?
Sunshine Biopharma reported an EPS of -$0.94 in its last earnings report, beating expectations of -$535. Following the earnings report the stock price went down -6.294%.
Which hedge fund is a major shareholder of Sunshine Biopharma?
Currently, no hedge funds are holding shares in SBFM
---
Company Description
Sunshine Biopharma
Sunshine Biopharma, Inc. engages in the the research, development and commercialization of drugs for the treatment of various forms of cancer. Its products include Adva-27a, SBI-Anastrozol, SBI-Letrozole, SBI-Bicalutamide, SBI-Finasteride, and Essential 9. The company was founded on August 31, 2006 and is headquartered in Montreal, Canada.
---
Technical Analysis
Aditxt, Inc.
―
CytoDyn
―
BioRestorative Therapies
―
Northwest Biotherapeutics
―
Advaxis
―
Oncology Pharma
―
---